There has been an evolution in clinical guidelines over the past decade regarding the indications for the treatment of chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) with sodium–glucose cotransporter 2 (SGLT-2) inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.